A single-institution experience with treatment of severe acute chest syndrome: lack of rebound pain with dexamethasone plus transfusion therapy.
The use of corticosteroid therapy for the treatment of acute chest syndrome (ACS) in patients with sickle cell disease has been infrequently used owing to concerns for rebound pain. Here, we report a cohort of patients<21 years of age with sickle cell disease treated between January 2001 and June 2006 for severe ACS with both corticosteroids and transfusion therapy. We reviewed 53 episodes of severe ACS with an average hospital duration of 4.9 days. Only 1 patient out of 6 who were transferred to the intensive care unit required intubation. None of the ACS episodes resulted in death and none of the 4 readmissions after discharge were due to pain. There was no acute toxicity related to either corticosteroid or transfusion therapy.
Isakoff
Michael S
MS
Division of Hematology/Oncology, Connecticut Children's Medical Center, Hartford, CT 06106, USA. misakoff@ccmckids.org
Lillo
J Alyssa
JA
Hagstrom
J Nathan
JN
D000293:Adolescent; D000420:Albuterol / Q000627:therapeutic use; D000755:Anemia, Sickle Cell / Q000150:complications*; D001993:Bronchodilator Agents / Q000627:therapeutic use; D002675:Child, Preschool; D005334:Fever / Q000209:etiology; D006801:Humans; D008171:Lung Diseases / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D010102:Oxygen Inhalation Therapy; D013902:Radiography, Thoracic; D013147:Spirometry
D001993:Bronchodilator Agents; D000420:Albuterol